Kintara Therapeutics Inc. (NASDAQ:KTRA) finished Wednesday with an addition of $0.04 to close at $1.00, an upside of 4.58 percent. An average of 4,795,200 shares of common stock have been traded in the last five days. There was a gain of $0.2398 in the past week. The last 20 days have seen an average of 3,381,065 shares traded, while the 50-day average volume stands at 1,450,858.
KTRA stock has decreased by -26.49% in the last month. The company shares reached their 1-month lowest point of $0.7400 on 10/05/21. With the stock rallying to its 52-week high on 02/10/21, shares of the company touched a low of $0.74 and a high of $3.35 in 52 weeks. In spite of this, the price is down -70.16% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Kintara Therapeutics Inc. (KTRA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 1.65.
The quick ratio of Kintara Therapeutics Inc. for the three months ended June 29 was 4.20, and the current ratio was 4.20, indicating that the company is able to meet its debt obligations.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Kintara Therapeutics Inc.’s return on assets was -218.40%, compared to -237.5% over the last five years. For the broader industry, ROE averaged -68.79 over the past year.
The analyst consensus anticipated Kintara Therapeutics Inc.’s latest quarter earnings to come in at -$0.16 per share, but it turned out to be -$0.13, a 18.80% surprise. For the quarter, EBITDA amounted to -$6.61 million. At the end of the quarter ending June 29, Kintara Therapeutics Inc.’s stock balance sheet showed total liabilities of 2.96 million. Shareholders own equity worth $43.17 million.
From a technical analysis perspective, let’s take a brief look at Kintara Therapeutics Inc. (KTRA) price momentum. RSI 9-day as of the close on 13 October was 55.50%, suggesting the stock is Neutral, with historical volatility in this time frame at 96.72%.
As of today, KTRA’s price is $0.8712 +31.55% or $0.2398 from its 5-day moving average. KTRA is currently trading -25.39% lower than its 20-day SMA and -34.65% lower than its 100-day SMA. However, the stock’s current price level is -33.35% below the SMA50 and -27.55% below the SMA200.
The stochastic %K and %D were 43.06% and 23.11%, respectively, and the average true range (ATR) was 0.1029. With the 14-day stochastic at 76.41% and the average true range at 0.1013, the RSI (14) stands at 46.22%. The stock has reached 0.0948 on the 9-day MACD Oscillator while the 14-day reading was at 0.0859.
The consensus rating for Kintara Therapeutics Inc. (KTRA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell KTRA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is KTRA’s price target for the next 12 months?
Analysts predict a range of price targets between $3.00 and $6.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Kintara Therapeutics Inc. (KTRA) stock is $4.85.